Newsroom

Immunexpress to Present Data at ISICEM 2023 Indicating that SeptiCyte® RAPID Outperforms Other Rapid Measures for Sepsis Diagnosis

March 31, 2023

Immunexpress Begins US Commercialization of Near-Patient Sepsis Diagnostic Test

February 3, 2023

New Publication Validates SeptiCyte® RAPID as a Triaging Tool for COVID-19 Patients

February 2, 2023

SeptiCyte RAPID accurately assessed COVID-19 severity Elevated SeptiScore upon hospital intake was predictive of ICU admission SeptiCyte RAPID performed better than single-biomarker assays that are routinely used to assess COVID-19 severity SEATTLE and BRISBANE, Australia, Feb. 2, 2023 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving...

At AMP 2022, Immunexpress launches rapid test for sepsis requiring two minutes hands-on time

November 14, 2022

From Leo O'Connor of LabPulse.com At the Association for Molecular Pathology annual meeting and exposition this week, Immunexpress launched a rapid molecular diagnostic test that could enable ruling in or ruling out sepsis in one hour. The SeptiCyte Rapid test is different from almost all other sepsis tests on the market by...

A multi-site study confirms the use of undiluted EDTA blood for the SeptiCyte RAPID sepsis assay

November 14, 2022

Data Validating EDTA Blood as Sample Type for SeptiCyte® RAPID Presented at the Association for Molecular Pathology 2022 Annual Meeting SEATTLE and BRISBANE, Australia, Nov. 3, 2022 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today the presentation of an abstract at the Association for...

Screenshot from ContagionLive interview with Dr. Roy Davis

ContagionLive interview: A Rapid Sepsis Diagnostic Test for Better Patient Outcomes

October 27, 2022

Nina Cosdon of ContagionLive interviewed the chief medical officer of Immunexpress Inc., Roy Davis, MD, PhD, MHA, in a post titled A Rapid Sepsis Diagnostic Test for Better Patient Outcomes. Sepsis diagnosis often takes days. Dr. Roy Davis and his team have developed a test that can diagnose sepsis in...

CEO Rolland Carlson: When Advancing a Medical Device, Be A Partner First & Seller Second to Hospital Systems

October 27, 2022

Immunexpress CEO Rolland Carlson was recently featured on HITConsultant, which provides healthcare technology news, analysis and insights for healthcare executives, physicians and providers. "US hospital systems validate the safety, clinical utility, and robustness of newly FDA-approved devices, 510(k) cleared, before adopting them into clinical practice. This work occurs alongside evaluating...

Dr. Rollie Carlson was interviewed for Docwire News

Interview with DocWireNew: Dr. Rollie Carlson, CEO, Immunexpress: Providing RAPID Detection for Sepsis

September 26, 2022

DocWire News spoke with Dr. Rollie Carlson, CEO of Immunexpress, to learn more about this cutting-edge technology, and how it can quickly and accurately detect sepsis, and lead to faster treatment. https://youtu.be/Vd0FL3fYPwY

Interview with Dr Rolland Carlson and Dr Richard Brandon

September 19, 2022

Download the Drug Target Review interview with Dr. Rolland Carlson and Dr. Richard Brandon.(pdf) The 2022 Drug Target Review Assays ebook, includes an interview about our sepsis detection initiative. In this collection of articles, Dr. Rolland Carlson and Dr. Richard Brandon, Immunexpress, answer questions about molecular...

Immunexpress Announces the Launch of New SeptiCyte RAPID® CE-IVD EDTA Blood Compatible Cartridges

August 23, 2022

SEATTLE, Aug. 23, 2022 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today the launch of new SeptiCyte RAPID® EDTA blood compatible cartridges for the European market. The updated SeptiCyte® RAPID CE-IVD cartridge adds undiluted EDTA blood as a validated sample type, representing...

A Paradigm Shift in Sepsis Diagnostics

August 5, 2022

By Anna MacDonald of Technology Networks Immunexpress is advancing next-generation clinical sepsis diagnosis tests for use in emergency room and intensive care unit settings. The company’s lead test SeptiCyte® RAPID is clinically validated and has received 510(k) FDA clearance indicated for the diagnosis of sepsis in adults. It is the...

Tips For Obtaining Your 510(k) FDA Clearance

July 10, 2022

By Rolland Carlson, Ph.D., CEO, Immunexpress Our SeptiCyte RAPID clinical test received 510(k) FDA clearance indicated for the diagnosis of sepsis in adults. Sepsis is a life-threatening medical condition. Every minute counts for these patients in the ER and ICU. Clinicians in these settings need processes to distinguish sepsis patients...